These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18256540)

  • 1. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.
    Malanga D; Scrima M; De Marco C; Fabiani F; De Rosa N; De Gisi S; Malara N; Savino R; Rocco G; Chiappetta G; Franco R; Tirino V; Pirozzi G; Viglietto G
    Cell Cycle; 2008 Mar; 7(5):665-9. PubMed ID: 18256540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias.
    Kim MS; Jeong EG; Yoo NJ; Lee SH
    Br J Cancer; 2008 May; 98(9):1533-5. PubMed ID: 18392055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.
    Askham JM; Platt F; Chambers PA; Snowden H; Taylor CF; Knowles MA
    Oncogene; 2010 Jan; 29(1):150-5. PubMed ID: 19802009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rarity of AKT1 and AKT3 E17K mutations in squamous cell carcinoma of lung.
    Do H; Salemi R; Murone C; Mitchell PL; Dobrovic A
    Cell Cycle; 2010 Nov; 9(21):4411-2. PubMed ID: 20980808
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutant AKT1-E17K is oncogenic in lung epithelial cells.
    De Marco C; Malanga D; Rinaldo N; De Vita F; Scrima M; Lovisa S; Fabris L; Carriero MV; Franco R; Rizzuto A; Baldassarre G; Viglietto G
    Oncotarget; 2015 Nov; 6(37):39634-50. PubMed ID: 26053093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A computational approach for investigating the mutational landscape of RAC-alpha serine/threonine-protein kinase (AKT1) and screening inhibitors against the oncogenic E17K mutation causing breast cancer.
    Thirumal Kumar D; Jain N; Evangeline J; Kamaraj B; Siva R; Zayed H; George Priya Doss C
    Comput Biol Med; 2019 Dec; 115():103513. PubMed ID: 31698236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain.
    Landgraf KE; Pilling C; Falke JJ
    Biochemistry; 2008 Nov; 47(47):12260-9. PubMed ID: 18954143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.
    Rudolph M; Anzeneder T; Schulz A; Beckmann G; Byrne AT; Jeffers M; Pena C; Politz O; Köchert K; Vonk R; Reischl J
    BMC Cancer; 2016 Aug; 16():622. PubMed ID: 27515171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
    Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
    Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AKT1(E17K) in human solid tumours.
    Bleeker FE; Felicioni L; Buttitta F; Lamba S; Cardone L; Rodolfo M; Scarpa A; Leenstra S; Frattini M; Barbareschi M; Grammastro MD; Sciarrotta MG; Zanon C; Marchetti A; Bardelli A
    Oncogene; 2008 Sep; 27(42):5648-50. PubMed ID: 18504432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis.
    Mancini ML; Lien EC; Toker A
    Oncotarget; 2016 Apr; 7(14):17301-13. PubMed ID: 27004402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.
    Shoji K; Oda K; Nakagawa S; Hosokawa S; Nagae G; Uehara Y; Sone K; Miyamoto Y; Hiraike H; Hiraike-Wada O; Nei T; Kawana K; Kuramoto H; Aburatani H; Yano T; Taketani Y
    Br J Cancer; 2009 Jul; 101(1):145-8. PubMed ID: 19491896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
    Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
    Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
    De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
    PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells.
    Guo G; Qiu X; Wang S; Chen Y; Rothman PB; Wang Z; Chen Y; Wang G; Chen JL
    Oncogene; 2010 Jul; 29(26):3845-53. PubMed ID: 20440266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.
    Carpten JD; Faber AL; Horn C; Donoho GP; Briggs SL; Robbins CM; Hostetter G; Boguslawski S; Moses TY; Savage S; Uhlik M; Lin A; Du J; Qian YW; Zeckner DJ; Tucker-Kellogg G; Touchman J; Patel K; Mousses S; Bittner M; Schevitz R; Lai MH; Blanchard KL; Thomas JE
    Nature; 2007 Jul; 448(7152):439-44. PubMed ID: 17611497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E17K substitution in AKT1 in prostate cancer.
    Boormans JL; Korsten H; Ziel-van der Made AC; van Leenders GJ; Verhagen PC; Trapman J
    Br J Cancer; 2010 May; 102(10):1491-4. PubMed ID: 20407443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AKT Inhibition in Solid Tumors With AKT1 Mutations.
    Hyman DM; Smyth LM; Donoghue MTA; Westin SN; Bedard PL; Dean EJ; Bando H; El-Khoueiry AB; Pérez-Fidalgo JA; Mita A; Schellens JHM; Chang MT; Reichel JB; Bouvier N; Selcuklu SD; Soumerai TE; Torrisi J; Erinjeri JP; Ambrose H; Barrett JC; Dougherty B; Foxley A; Lindemann JPO; McEwen R; Pass M; Schiavon G; Berger MF; Chandarlapaty S; Solit DB; Banerji U; Baselga J; Taylor BS
    J Clin Oncol; 2017 Jul; 35(20):2251-2259. PubMed ID: 28489509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling.
    Gao SP; Kiliti AJ; Zhang K; Vasani N; Mao N; Jordan E; Wise HC; Shrestha Bhattarai T; Hu W; Dorso M; Rodrigues JA; Kim K; Hanrahan AJ; Razavi P; Carver B; Chandarlapaty S; Reis-Filho JS; Taylor BS; Solit DB
    Mol Cancer Res; 2021 Apr; 19(4):573-584. PubMed ID: 33303690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.